A narrative literature review of the incidence and prevalence of safety outcomes in patients with ulcerative colitis.

IF 3.8 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Expert Review of Gastroenterology & Hepatology Pub Date : 2025-06-01 Epub Date: 2025-05-13 DOI:10.1080/17474124.2025.2501224

Milena Gianfrancesco, Abiola Awofeso, Diogo Branquinho, Xiang Guo, Aoibhinn McDonnell, Wilco Jacobs, Miguel Regueiro

{"title":"A narrative literature review of the incidence and prevalence of safety outcomes in patients with ulcerative colitis.","authors":"Milena Gianfrancesco, Abiola Awofeso, Diogo Branquinho, Xiang Guo, Aoibhinn McDonnell, Wilco Jacobs, Miguel Regueiro","doi":"10.1080/17474124.2025.2501224","DOIUrl":null,"url":null,"abstract":"Introduction: Information on rates of safety outcomes in patients with ulcerative colitis [UC] is helpful to better understand the benefit-risk profile of more recent therapies approved for UC.Areas covered: This narrative review provides an updated examination of the incidence and prevalence of safety outcomes in the UC patient population. Incidence and prevalence estimates were determined for outcomes including cardiac conduction disorders, infections, and malignancies from published literature [2013-2023].Expert opinion: While information for certain outcomes was more frequently recorded, such as herpes viral infection (incidence rate [IR] 0.0-4.47 per 100 person-years [PY]) and malignancies [all; IR 0.0-1.77 per 100 PY], rarer outcome estimates such as bradycardia [IR 0.2 per 100 PY] and macular edema [IR 0.2 per 100 PY] were limited. Our knowledge of certain, uncommon safety outcomes and concomitant medical conditions in the UC population remains limited given the lack of data available. Even though larger cohorts with longer follow-up are warranted, estimates provided in this review will contribute to an improved understanding of the safety profile of UC therapies.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"639-656"},"PeriodicalIF":3.8000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Gastroenterology & Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17474124.2025.2501224","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/13 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Information on rates of safety outcomes in patients with ulcerative colitis [UC] is helpful to better understand the benefit-risk profile of more recent therapies approved for UC.

Areas covered: This narrative review provides an updated examination of the incidence and prevalence of safety outcomes in the UC patient population. Incidence and prevalence estimates were determined for outcomes including cardiac conduction disorders, infections, and malignancies from published literature [2013-2023].

Expert opinion: While information for certain outcomes was more frequently recorded, such as herpes viral infection (incidence rate [IR] 0.0-4.47 per 100 person-years [PY]) and malignancies [all; IR 0.0-1.77 per 100 PY], rarer outcome estimates such as bradycardia [IR 0.2 per 100 PY] and macular edema [IR 0.2 per 100 PY] were limited. Our knowledge of certain, uncommon safety outcomes and concomitant medical conditions in the UC population remains limited given the lack of data available. Even though larger cohorts with longer follow-up are warranted, estimates provided in this review will contribute to an improved understanding of the safety profile of UC therapies.

查看原文本刊更多论文

溃疡性结肠炎患者安全性结局的发生率和患病率的叙述性文献综述。

关于溃疡性结肠炎（UC）患者安全结局率的信息有助于更好地理解最近批准的UC治疗的获益-风险概况。涵盖领域：这篇叙述性综述提供了UC患者群体中安全性结果的发生率和流行率的最新研究。从已发表的文献[2013-2023]中确定了包括心传导障碍、感染和恶性肿瘤在内的预后的发病率和患病率估计。专家意见：虽然某些结果的信息更频繁地记录，如疱疹病毒感染（发病率[IR] 0.04.47 / 100人年[PY]）和恶性肿瘤[所有；IR为0.0-1.77 / 100 PY)，而心动过缓（IR为0.2 / 100 PY）和黄斑水肿（IR为0.2 / 100 PY）等较为罕见的预后评估受到限制。由于缺乏可用的数据，我们对UC人群中某些不常见的安全结果和伴随医疗状况的了解仍然有限。尽管需要更大的队列和更长的随访时间，但本综述提供的估计将有助于提高对UC治疗安全性的理解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Gastroenterology & Hepatology GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

6.80

自引率

2.60%

发文量

审稿时长

6-12 weeks

期刊介绍： The enormous health and economic burden of gastrointestinal disease worldwide warrants a sharp focus on the etiology, epidemiology, prevention, diagnosis, treatment and development of new therapies. By the end of the last century we had seen enormous advances, both in technologies to visualize disease and in curative therapies in areas such as gastric ulcer, with the advent first of the H2-antagonists and then the proton pump inhibitors - clear examples of how advances in medicine can massively benefit the patient. Nevertheless, specialists face ongoing challenges from a wide array of diseases of diverse etiology.